Skip to Content

3SBio Inc

Rating as of

Company Profile

Business Description

3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2018, it reported revenue of CNY 4.6 billion. Approximately 75% of its revenue is derived from three core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), and EPIAO (rhEPO), which are all older generation biologics. The company has a pipeline of 32 products, of which 22 are biologics and 10 are small molecules. Only two of these products are expected to launch within the next year: inetetamab (biosimilar of trastuzumab, a HER2 down-regulator) and Jiantuoxi (biosimilar of rituximab, an anti-CD20 antibody).

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone
Shenyang, 110027, Cayman Islands
T +86 2425386000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings
Fiscal Year End Dec 31, 2019
Stock Type
Employees 5,404